Dosage ; Up to 30mg daily (orally). 20-200mg 1.M every 2-4 weeks
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Fluanxol depot | Lundbeck Laboratories | Jos Hansen (E.A) Ltd | 20mg | 1 | Injection | per vial | KES 874.00 |
| Fluanxol depot | Lundbeck Laboratories | Jos Hansen (E.A) Ltd | 40mg | 1 | Injection | per vial | KES 1,266.00 |
| Fluanxol | Lundbeck Laboratories | Jos Hansen (E.A) Ltd | 0.5mg | 100 | Tablet | per tablet | KES 1,315 |
| Fluanxol | Lundbeck Laboratories | Jos Hansen (E.A) Ltd | 3mg | 100 | Tablet | per tablet | KES 4,200.00 |
|
Flupenthixol More info |
|
|---|---|
| Mode Of Action | Blocking of postsynaptic dopamine receptors in the brain. Also producing alpha-adrenergic blocking effect and depresses the release of most hypothalamic and hypophyseal hormones. |
| Drug Indication | Psychosis; schizophrenia; depression with or without anxiety. |
| Precautions | Avoid abrupt withdrawal, extremes of body temperatures, epilepsy and skin contact. |
| Contra-Indications | Parkinsonism, myasthenia gravis, concomitant use with CNS depressants, diabetes mellitus, bone marrow depression, close angle glaucoma, hepatic, renal, CVS impairment, phaeochromocytosis, hyperthyroidism. |
| Side Effects | Extrapyramidal symptoms; akathisia; dystonic reactions; persistent tardive dyskinesia; allergic reaction; anticholinergic effects; deposition of opaque substances in lens and cornea; retinopathy; hypotension; skin discoloration; blood dyscrasias; heat stroke; obstructive jaundice, neuroleptic malignant syndrome; tardive dystonia; constipation; drowsiness, insomnia, nightmare, hypothermia, apathy, pallor, convulsions, anti-muscarinic symptoms, nasal congestion, sudden death, ECG changes, SLE-like |
| Dosage | Up to 30mg daily (orally). 20-200mg 1.M every 2-4 weeks |
| Special Information | Exceptions: Less sedative; higher frequency of extrapyramidal symptoms. |
| Pregnancy Category | Category B1 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals have not shown evidence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Hypnotics, sedatives & tranquilizers
Specific dosages; Use Maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity Dosing: Adult Psychotic symptoms: I.M.: Note: Flupenthixol is administered by deep I.M. injection, preferably in the gluteus maximus, not for I.V. use; maintenance dosages are given at 2- to 3-week intervals Test dose: Patients not previously treated with long-acting depot neuroleptics should be given an initial test dose of 5-20 mg. An initial dose of 20 mg is usually well tolerated; however, a 5 mg test dose is recommended in elderly, frail, and cachectic patients, and in patients whose individual or family history suggests a predisposition to extrapyramidal reactions. In the subsequent 5-10 days, the therapeutic response and the appearance of extrapyramidal symptoms should be carefully monitored. Oral neuroleptic drugs may be continued, but dosage should be reduced during this overlapping period and eventually discontinued. Oral: Initial: 1 mg 3 times/day; dose must be individualized. May be increased by 1 mg every 2-3 days based on tolerance and control of symptoms. Usual maintenance dosage: 3-6 mg/day in divided doses (doses ≥12 mg/day used in some patients). Dosing: Geriatric Refer to adult dosing |